Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
VCYT vs CDNA: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
CDNA Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 6–4 Matrix Metrics)
CDNA Overall Winner
6-Pillar Tally: VCYT 3 – 3 CDNA
Matrix Metrics: VCYT 4 – 6 CDNA
As of Nov 16, 2026, CareDx, Inc. (CDNA) is the stronger overall head-to-head candidate over Veracyte, Inc. (VCYT) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Growth & Scale, Options & Positioning, R&D & Supply-Chain Moat). VCYT carries a Unified Composite Score of 49.1/100 (HOLD) at $24.01 (15.3x Forward P/E, 15.0% operating margin), whereas CDNA carries 24.5/100 (STRONG SELL) at $73.72 (47.1x Forward P/E, 1.6% operating margin).
- Composite vs. Pillar Nuance: While VCYT currently prints a higher short-term Unified Composite Score (49.1/100 HOLD vs. CDNA 24.5/100 STRONG SELL), CDNA captures the overall institutional head-to-head verdict (6–4 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (1.6% vs. 15.0% operating margin) and revenue trajectory (+39.3% vs. +15.1% YoY).
- Technical & Structure Timing Caution: VCYT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 27.8); meanwhile CDNA trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 49.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About VCYT vs CDNA
VCYT
Veracyte, Inc.
$24.01
-1.32% 1D
Market Cap
$2.0B
TTM Revenue
$582M
Forward P/E
15.3x
Beta / 30D Vol
3.01β · 199% Vol
Unified Composite Score
49.1
HOLD
Tech 55.0
Fund 56.0
Flow 57.0
Mom 55.0
Weinstein Technical Phase
Markdown · Sell / avoid
CDNA
Head-to-Head Winner
CareDx, Inc.
$73.72
-5.34% 1D
Market Cap
$4.1B
TTM Revenue
$497M
Forward P/E
47.1x
Beta / 30D Vol
1.21β · 98% Vol
Unified Composite Score
24.5
STRONG SELL
Tech 15.0
Fund 36.0
Flow 70.0
Mom 25.9
Weinstein Technical Phase
Neutral · Hold
6-Pillar Scorecard Institutional Category Breakdown (VCYT 3 – 3 CDNA)
1. Valuation Multiples
VCYT
Forward P/E
15.3x
47.1x
Trailing P/E
15.8x
32.9x
PEG Ratio
N/M
N/M
EV / Revenue
3.1x
7.8x
2. Growth & Scale
CDNA
Revenue Growth (YoY)
+15.1%
+39.3%
Earnings Growth (YoY)
+58.3%
N/A
TTM Revenue (USD)
$582M
$497M
Market Cap
$2.0B
$4.1B
3. Profitability & Quality
VCYT
Gross Margin
74.2%
71.0%
Operating Margin
15.0%
1.6%
Net Profit Margin
21.8%
25.9%
Return on Equity (ROE)
9.4%
33.0%
4. Balance Sheet & Cash Flow
VCYT
Cash Generation (TTM)
$162M
$60M
Cash Flow Margin
27.8%
12.0%
Net Cash / Leverage
$159M Net Cash
$221M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
CDNA
Options Structure Phase
BREAKDOWN
CONSOLIDATION
Current IV / %ile
197.3% (47th %ile)
56.8% (18th %ile)
Put/Call OI Skew
0.01x (Call-Skewed)
1.04x (Balanced)
OBV Trend / Tech Phase
DISTRIBUTION · Markdown
NEUTRAL · Neutral
6. R&D & Supply-Chain Moat
CDNA
OpEx & R&D Intensity
59.2% of Rev ($344M)
69.4% of Rev ($345M)
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Scale & Operating Efficiency Moat
Scale & Operating Efficiency Moat
Supply-Chain Role
Diagnostics & Research Operator
Diagnostics & Research Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: VCYT (4) vs CDNA (6)| Institutional Metric | VCYT | CDNA | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $2.0B | $4.1B | CDNA | |
| Trailing P/E Ratio | 15.8x | 32.9x | VCYT | |
| Forward P/E Ratio | 15.3x | 47.1x | VCYT | |
| Revenue Growth (YoY) | +15.1% | +39.3% | CDNA | |
| Operating Margin (TTM) | 15.0% | 1.6% | VCYT | |
| Net Profit Margin | 21.8% | 25.9% | CDNA | |
| Return on Equity (ROE) | 9.4% | 33.0% | CDNA | |
| 52-Week Range Position | 5% ($22–$61) | 77% ($15–$91) | CDNA | |
| Beta / 30D Volatility | 3.01β · 199% Vol | 1.21β · 98% Vol | CDNA | |
| Unified Institutional Score | 49.1 / 100 (HOLD) | 24.5 / 100 (STRONG SELL) | VCYT | |
| Trailing 12M Revenue (USD) | $582M | $497M | Scale | |
| Gross Profit Margin (TTM) | 74.2% | 71.0% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 3.1x EV/Rev | N/M PEG · 7.8x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | $162M ($159M Net Cash) | $60M ($221M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
CDNA +59.51 pp
3M Horizon
CDNA +100.62 pp
6M Horizon
CDNA +300.18 pp
1Y Horizon
CDNA +404.3 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | VCYT Revenue | CDNA Revenue | VCYT Op. Margin | CDNA Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2018 | $90M | $80M | -24.2% | -20.3% | CDNA |
| FY2019 | $120M | $130M | -12.6% | -19.3% | VCYT |
| FY2020 | $120M | $190M | -30.1% | -11.7% | CDNA |
| FY2021 | $220M | $300M | -37.3% | -10.0% | CDNA |
| FY2022 | $300M | $320M | -13.9% | -24.0% | VCYT |
| FY2023 | $360M | $280M | -23.8% | -72.5% | VCYT |
| FY2024 | $450M | $330M | 3.6% | 12.2% | CDNA |
| FY2025 | $520M | $380M | 11.2% | -8.1% | VCYT |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
VCYT
BREAKDOWN
Current IV
197.3%
IV Percentile
47th %ile
Put/Call OI Skew
0.01x (Call-Skewed)
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BEARISH
OBV Flow
DISTRIBUTION
Exact VCYT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
CDNA
CONSOLIDATION
Current IV
56.8%
IV Percentile
18th %ile
Put/Call OI Skew
1.04x (Balanced)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact CDNA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
VCYT Moat Profile
Scale & Operating Efficiency Moat
Diagnostics & Research Operator
OpEx & R&D Reinvestment
59.2% of Rev ($344M)
90D Engineering Disclosures
0 Published
CDNA Moat Profile
Scale & Operating Efficiency Moat
Diagnostics & Research Operator
OpEx & R&D Reinvestment
69.4% of Rev ($345M)
90D Engineering Disclosures
0 Published
Investor FAQ VCYT vs CDNA Key Questions & Quantitative Answers
As of Nov 16, 2026, CareDx, Inc. (CDNA) is the stronger overall head-to-head candidate over Veracyte, Inc. (VCYT) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Growth & Scale, Options & Positioning, R&D & Supply-Chain Moat). VCYT carries a Unified Composite Score of 49.1/100 (HOLD) at $24.01 (15.3x Forward P/E, 15.0% operating margin), whereas CDNA carries 24.5/100 (STRONG SELL) at $73.72 (47.1x Forward P/E, 1.6% operating margin). Composite vs. Pillar Nuance: While VCYT currently prints a higher short-term Unified Composite Score (49.1/100 HOLD vs. CDNA 24.5/100 STRONG SELL), CDNA captures the overall institutional head-to-head verdict (6–4 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (1.6% vs. 15.0% operating margin) and revenue trajectory (+39.3% vs. +15.1% YoY). Technical & Structure Timing Caution: VCYT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 27.8); meanwhile CDNA trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 49.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
CDNA leads the Growth & Scale pillar: VCYT posts +15.1% YoY revenue growth and +58.3% YoY earnings growth on $582M TTM revenue (74.2% gross margin, 15.0% operating margin), compared with CDNA at +39.3% YoY revenue growth and N/A YoY earnings growth on $497M TTM revenue (71.0% gross margin, 1.6% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), VCYT cumulative revenue shifted +477.8% while CDNA shifted +375.0%. In operating R&D and SG&A reinvestment, VCYT deploys 59.2% of Rev ($344M) (0 90-day corporate R&D disclosures) versus 69.4% of Rev ($345M) (0 disclosures) for CDNA.
VCYT screens cheaper on headline valuation multiples. VCYT trades at 15.3x Forward P/E, 15.8x Trailing P/E, N/M PEG, and 3.1x EV/Revenue (27.8% FCF margin), whereas CDNA trades at 47.1x Forward P/E, 32.9x Trailing P/E, N/M PEG, and 7.8x EV/Revenue (12.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VCYT (9.4% ROE) versus CDNA (33.0% ROE) capital efficiency.
In options market volatility and institutional positioning, VCYT carries 197.3% implied volatility (47th %ile, Balanced (25th–60th %ile)), a 0.01x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (3.01β · 199% Vol realized risk). By comparison, CDNA carries 56.8% implied volatility (18th %ile, Compressed (<25th %ile)), a 1.04x (Balanced) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.21β · 98% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
CDNA vs VCYT · Reverse Pair
VCYT vs TWST
· Sector Peer
VCYT vs TXG
· Sector Peer
VCYT vs PSNL
· Sector Peer
CDNA vs TWST
· Sector Peer
CDNA vs PSNL
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem